HOUSTON--(BUSINESS WIRE)--Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company was selected for a poster presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held from June 3 – 7 in Chicago, IL.
Also in June, data from the ongoing BP-004 clinical trial of BPX-501, the Company’s adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation, will be discussed by Dr. Alice Bertaina, Head of Stem Cell Transplant at Ospedale Pediatrico Bambino Gesù in an oral presentation at the 21st Congress of the European Hematology Association (EHA) being held from June 9 – 12 in Copenhagen, Denmark.
ASCO Presentation Details:
Presentation Title: “Enhanced efficacy and safety of
Her2-targeted chimeric antigen receptor (CAR) T cells using MyD88/CD40
costimulation and iCaspase-9 suicide switch”
Abstract Number: 3050
Poster Board: #372
Session Name: Developmental Therapeutics - Immunotherapy
Date: Sunday, June 5, 2016
Presentation Time: 8:00 AM - 11:30 AM CDT (9:00 AM – 12:30 PM EDT)
EHA Oral Presentation Details:
Presentation Title: “Infusion of BPX-501 (donor T cells
transduced with the iC9 suicide gene) after α/β T-cell depleted
haplo-HSCT in children with acute leukemia: Preliminary results of a
Phase I-II trial”
Abstract Number: S523
Session Name: Stem cell transplantation - Clinical 1
Date: Saturday, June 11, 2016
Presentation Time: 4:30 PM - 4:45 PM CEST (10:30 AM – 10:45 AM EDT)
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Bellicum may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," “designed,” "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities relating to rimiducid, CID, CAR, TCR, MyD88/CD40 and iCaspase9; the effectiveness of rimiducid and of BPX-501, their possible range of application and potential curative effects and safety in the treatment of diseases; the timing and success of our clinical trials, including our BP-004 clinical protocol; the timing of regulatory filings for BPX-501 and for rimiducid; our research and development activities relating to BPX-501 and rimiducid; and the potential applications and effectiveness of our product candidates BPX-501 and rimiducid, including as compared to other treatment options and competitive therapies. Various factors may cause differences between Bellicum’s expectations and actual results as discussed in greater detail under the heading “Risk Factors” in Bellicum’s filings with the Securities and Exchange Commission, including without limitation our annual report on Form 10-K for the year ended December 31, 2015. Any forward-looking statements that Bellicum makes in this press release speak only as of the date of this press release. Bellicum assumes no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.